Technical Analysis for NYMX - Nymox Pharmaceutical Corporation

Grade Last Price % Change Price Change
grade B 1.76 -1.68% -0.03
NYMX closed down 1.68 percent on Wednesday, August 21, 2019, on 39 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical NYMX trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
200 DMA Resistance Bearish -1.68%
Shooting Star Candlestick Bearish -1.68%
Crossed Above 20 DMA Bullish -1.68%
Bollinger Band Squeeze Range Contraction -1.68%
20 DMA Resistance Bearish 1.15%
Bollinger Band Squeeze Range Contraction 1.15%
Narrow Range Bar Range Contraction 1.15%

Older signals for NYMX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development, and commercialization of drugs and diagnostic products for the aging population in the United States, Canada, Europe, and other countries. It provides AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimer's disease; and NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The company's products under development include NX-1207, which in Phase III clinical trials for the treatment of benign prostatic hyperplasia, as well as in human clinical trials to treat hepatocellular carcinoma and localized prostate cancer; and NXC-4720, an antibacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. In addition, the company is involved in the research and development of drugs at various treatments for Alzheimer's disease and other indications; drugs for the treatment of Alzheimer's disease that targets spherons; and neural thread protein-based drugs, as well as developing various therapeutic products that are in the preclinical stage for oncology indications. It has license and collaboration agreement with Recordati Ireland Ltd. for the development and commercialization of NX-1207. The company was founded in 1989 and is headquartered in Saint Laurent, Canada.
Medicine Biopharmaceutical Food Medical Specialties Infection Alzheimer's Disease Therapeutic Products Tobacco Products Diagnostic Products Bacterial Infections Hepatocellular Carcinoma Bacterial Diseases Benign Prostatic Hyperplasia Treatment Of Alzheimer's Disease Pathogenic Bacteria Urinary Tract Infection Treatment Of Benign Prostatic Hyperplasia
Is NYMX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.93
52 Week Low 1.25
Average Volume 161,551
200-Day Moving Average 1.8499
50-Day Moving Average 1.681
20-Day Moving Average 1.7685
10-Day Moving Average 1.754
Average True Range 0.1249
ADX 24.7
+DI 26.4356
-DI 12.5715
Chandelier Exit (Long, 3 ATRs ) 1.6253
Chandelier Exit (Short, 3 ATRs ) 1.9747
Upper Bollinger Band 1.8988
Lower Bollinger Band 1.6382
Percent B (%b) 0.47
BandWidth 14.735652
MACD Line 0.0181
MACD Signal Line 0.0275
MACD Histogram -0.0094
Fundamentals Value
Market Cap 92.16 Million
Num Shares 52.4 Million
EPS -0.23
Price-to-Earnings (P/E) Ratio -7.65
Price-to-Sales 1081.14
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.91
Resistance 3 (R3) 1.92 1.89 1.89
Resistance 2 (R2) 1.89 1.85 1.88 1.88
Resistance 1 (R1) 1.82 1.82 1.81 1.81 1.87
Pivot Point 1.79 1.79 1.78 1.78 1.79
Support 1 (S1) 1.72 1.75 1.71 1.71 1.65
Support 2 (S2) 1.69 1.72 1.68 1.64
Support 3 (S3) 1.62 1.69 1.64
Support 4 (S4) 1.61